MK8245

Base Information

• Chemical Name: MK8245
• CAS No.: 1030612-90-8
• Molecular Formula: C17H16BrFN6O4
• Molecular Weight: 467.254
• Mol file: 1030612-90-8.mol

Synonyms:MK 8245;

Chemical Property of MK8245

Chemical Property:

• Boiling Point: 698.3±65.0 °C(Predicted)
• PKA: 2.85±0.10(Predicted)
• PSA: 119.40000
• Density: 1.82
• LogP: 2.42710
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility.: ≥23.35 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

Purity/Quality:

99%, ^*data from raw suppliers

MK8245 >98% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• General Description: MK8245 is a potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitor developed to treat metabolic disorders like obesity and type II diabetes, with optimized liver selectivity to minimize systemic side effects.

Technology Process of MK8245

There total 12 articles about MK8245 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 94.0%

(5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-isoxazol-5-yl}tetrazol-2-yl)-acetic acid tert-butyl ester (1329632-66-7) → 2-(5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl}-2H-1,2,3,4-tetrazol-2-yl)acetic acid (1030612-90-8)

Guidance literature:

With formic acid; at 95 ℃; for 2h; Inert atmosphere; Large scale reaction;

DOI:10.1021/op200186d

Reference yield:

ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate (1030613-41-2) → 2-(5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl}-2H-1,2,3,4-tetrazol-2-yl)acetic acid (1030612-90-8)

Guidance literature:

ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate; With sodium hydroxide; water; In tetrahydrofuran; methanol; at 20 ℃; for 1h;

With hydrogenchloride; In water;

Reference yield:

4-(2-bromo-5-fluorophenoxy)-1-[5-(1H-tetrazol-5-yl)isoxazol-3-yl]-piperidine (1030613-40-1) + ethyl bromoacetate (105-36-2) → 2-(5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl}-2H-1,2,3,4-tetrazol-2-yl)acetic acid (1030612-90-8) + C17H16BrFN6O4

Guidance literature:

4-(2-bromo-5-fluorophenoxy)-1-[5-(1H-tetrazol-5-yl)isoxazol-3-yl]-piperidine; ethyl bromoacetate; With triethylamine; In tetrahydrofuran; for 2h; Reflux;

With ethanol; sodium hydroxide; at 20 ℃; for 3h;

DOI:10.1021/jm200319u

upstream raw materials:

ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate

4-(2-bromo-5-fluorophenoxy)piperidine

ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate

3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide

Refernces

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series

10.1016/j.bmcl.2011.12.002

The research explores the development of novel SCD inhibitors aimed at treating metabolic disorders such as obesity and type II diabetes. The study focuses on creating liver-targeted inhibitors to avoid adverse effects observed in previous systemic SCD inhibitors. Key chemicals used include MK-8245, a potent liver-selective SCD inhibitor, and various bispyrrolidine and piperazine derivatives. The researchers employed a systematic SAR (Structure-Activity Relationship) study to optimize these compounds, resulting in the identification of bispyrrolidine 20 and piperazine 21 as effective liver-targeted SCD inhibitors with improved in vitro and in vivo potency. These compounds demonstrated good liver selectivity and reduced adverse effects, suggesting a promising therapeutic profile for further development in preclinical and potentially clinical settings.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Please select Metric Ton KG G Pound L ML

Email:

Company name:

Valid Period:

Detailed Requirements:

• Sample
• MOQ
• GMP
• FDA
• Price
  FOB CIF CFR EXW
• Urgent purchase

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Remove

Submit

1

What can I do for you?
Get Best Price

Get Best Price for 1030612-90-8 MK8245

Send

Send

Metric Ton KG G Pound L ML

Send

Send